Belgium· BE-AMP-SAM449946-00

Vitekta 150 mg

A elvitegravir product containing elvitegravir, registered in Belgium by Gilead Sciences.

ATC J05AX11

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedVitekta 150 mgATCJ05AX11REGISTER NO.BE-AMP-SAM449946-00PACKS LISTED0CHECKEDSeptember 26, 2026

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Elvitegravir
Manufacturer
Gilead Sciences
Country
Belgium (BE)
ATC code
J05AX11
ATC class
Elvitegravir
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

45 interactions on record for elvitegravir.

Graded by severity as the source publishes them — 9 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Elvitegravir · interactions on record

45 records

  • 9 severe
  • 36 moderate

Most severe, free to view

  • Zinc sulfateA12CB01severe
  • Zinc gluconateA12CB02severe
  • Zinc acetateA16AX05severe
  • Zinc chlorideB05XA12severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Elvitegravir in 2 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All elvitegravir products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/99cd0f4c-cb9a-4d9d-8b74-e7e6c407323e
GET /v1/drugs/99cd0f4c-cb9a-4d9d-8b74-e7e6c407323e?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Film-coated tablet",
  "source": "afmps",
  "status": "REVOKED",
  "name_en": "Vitekta 150 mg",
  "name_fr": "Vitekta 150 mg",
  "name_nl": "Vitekta 150 mg",
  "amp_code": "SAM449946-00",
  "strengths": [
    "150.0000"
  ],
  "pack_count": 1,
  "substances": [
    "Elvitegravir"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Elvitegravir",
  "authorisation_numbers": [
    "EU/1/13/883/002"
  ]
}

See everything about elvitegravir.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.